Precedence Research

🚀 Prescription Weight Loss Medications Market: Where Pharma Meets Nutrition Innovation The global prescription weight loss medications market is entering a high-growth phase, driven by rising recognition of obesity as a chronic disease and the rapid adoption of GLP-1 therapies. What’s changing now? Nutrition majors are stepping in to complement drug-led weight loss. 📊 Market Outlook Market size: USD 12.38 billion (2025) Forecast: USD 40.30 billion by 2035 Growth rate: 12.53% CAGR (2026–2035) 🌍 Regional Highlights North America dominated with 42% market share in 2025, fueled by strong GLP-1 adoption Asia-Pacific is expected to grow at the fastest CAGR, backed by rising obesity rates and improving healthcare access 🥛 Nutrition Giants Enter the GLP-1 Ecosystem As GLP-1 therapies reshape weight management, food and nutrition companies are innovating to support drug-assisted weight loss: 🔹 Danone (August 2025) Danone launched Oikos Fusion, a drinkable yogurt formulated specifically for • individuals using GLP-1 drugs like Ozempic and Wegovy. • Supports muscle preservation and digestion during weight loss • 23g protein, 5g prebiotic fiber, enriched with vitamins D, B3, and B12 • Lactose-free, no added sugars • Available in strawberry, mixed forest fruit, and vanilla flavors 🔹 Nestlé (April 2025) Nestlé introduced a new range of protein-based drinks for people on weight loss journeys, including GLP-1 users. • Built on proprietary whey protein microgel technology • Designed to regulate appetite, stabilize blood sugar, and preserve muscle mass • Part of Nestlé’s broader push into weight management and personalized nutrition • Backed by 100+ whey protein patents filed over the past decade, including 11 patents supporting the microgel format 🏭 Leading Players in the Market Novo Nordisk | Eli Lilly and Company | Pfizer | Amgen | GSK | AstraZeneca | Roche | Rhythm Pharmaceuticals Inc. | Currax Pharmaceuticals LLC | Zealand Pharma | Viking Therapeutics, Inc. 🔍 Big Picture Takeaway The future of weight management is no longer drug-only. It’s becoming an integrated ecosystem where GLP-1 medications, clinical care, and functional nutrition work together to improve outcomes, preserve muscle, and enhance long-term metabolic health. 💡 Obesity treatment is evolving from prescriptions to personalized, holistic solutions. 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://lnkd.in/dVtNKYKM Dive into the full analysis here: https://lnkd.in/d2WjX5RU #GLP1 #WeightLossInnovation #ObesityCare #PharmaNutrition #PersonalizedNutrition #HealthcareTrends #MarketInsights #MetabolicHealth

🚀 We’re Hiring: Content Writer (Fresher) Precedence Research is looking for enthusiastic and detail-oriented freshers who are eager to build their career in research-driven content writing. 📌 Role Highlights: Create clear, data-backed content for reports, articles, and digital platforms. Learn industry-focused writing with real market exposure. 🎓 Who can apply: Fresh graduates with strong written English skills Interest in market research, business, or data-driven content 📩 How to apply: Share your CV at [email protected] Start your content journey with a global market research firm! #Hiring #ContentWriterJobs #FresherJobs #PrecedenceResearch #MarketResearch #ContentWriting #Careers #HiringFreshers #ResearchJobs

🔬 Recombinant Cell Culture Supplements Market: Accelerating the Future of Bioproduction The global recombinant cell culture supplements market is entering a strong growth phase, projected to rise from USD 1.13 billion in 2025 to USD 3.89 billion by 2035, expanding at a CAGR of 13.16%. This momentum reflects the rapid shift toward defined, animal-free, and scalable solutions across biopharmaceutical manufacturing, regenerative medicine, vaccines, and advanced research. 📊 Key Market Highlights ▪️ North America led in 2025 with ~38% revenue share ▪️ Asia Pacific is the fastest-growing region (CAGR ~13.2%) ▪️ Recombinant albumin dominated products; growth factors & cytokines show fastest growth ▪️ Biopharmaceutical production accounted for ~55% of demand ▪️ Powder formulations led the market, while liquid formats gain traction 🤖 AI’s Growing Role in Cell Culture Innovation Artificial intelligence is transforming cell culture optimization, enabling real-time monitoring, predictive formulation insights, automated protocol refinement, and improved reproducibility. These capabilities are becoming critical as cell therapies and complex biologics move toward commercialization. 🚀 What’s Driving Growth? ✔ Rising biologics, cell & gene therapies ✔ Regulatory push toward serum-free, animal-free media ✔ Expansion of CDMOs & CROs ✔ Strong manufacturing investments in North America & Asia Pacific 🌏 Where Are the Opportunities? Asia Pacific stands out with rapid expansion in biotech infrastructure, vaccine manufacturing, and clinical research, while CDMOs/CROs emerge as high-growth end users due to outsourcing trends. 🔎 Explore the full market outlook, segmentation, and competitive landscape: 👉 https://lnkd.in/dhJRKw9Q You can place an order or ask any questions. Please feel free to contact us at [email protected] |+1 804 441 9344 #Biopharmaceuticals #CellCulture #RecombinantProteins #LifeSciences #Biomanufacturing #CellTherapy #RegenerativeMedicine #AIinBiotech #MarketInsights #PrecedenceResearch

🌍 Industrial Filters Market Outlook: Growth, AI Innovation & Sustainability Trends The global industrial filters market is on a strong growth trajectory, driven by tighter environmental regulations, rapid industrialization, and smarter filtration technologies. 📊 Market Snapshot • Market size: USD 4.13 billion (2025) • Expected to reach USD 7.77 billion by 2035 • CAGR: 6.52% (2026–2035) Industries such as HVAC, semiconductors, automotive, chemicals, pharmaceuticals, and water treatment are accelerating adoption as air, gas, and water quality standards continue to rise. 🔑 Key Market Highlights ✔️ Asia-Pacific led the market in 2025 and remains the fastest-growing region ✔️ Air filters dominate today; dust collectors are growing the fastest ✔️ Non-woven fabrics lead media types, while nanofibers & composites gain momentum ✔️ Mechanical filtration remains dominant; membrane filtration is rising for precision use ✔️ Aftermarket & replacement sales lead, with B2B e-commerce growing rapidly 🤖 How AI Is Transforming Industrial Filtration Artificial Intelligence is enabling smart, adaptive filtration systems that optimize performance in real time based on pollutant levels, airflow, humidity, and temperature. AI-driven predictive maintenance, inventory forecasting, and visual quality inspection are helping manufacturers reduce downtime, cut waste, and improve compliance in critical industrial environments. 🏢 Leading Players Shaping the Market 3M | Alfa Laval | Donaldson | Filtration Group | Freudenberg | Pall | Camfil | Cummins | Eaton 🔍 Recent Innovations • Donaldson’s partnership with Daimler Truck on hydrogen fuel cell filtration • R-Zero’s smart HVAC filters are improving efficiency in data centers & healthcare facilities 📥 Access the full market report covering size, share, CAGR, segmentation, and competitive landscape: 👉 https://lnkd.in/dDX7g8qP 📩 For inquiries or orders: [email protected] | 📞 +1 804 441 9344 #IndustrialFilters #MarketInsights #AirQuality #Sustainability #SmartManufacturing #AIinIndustry #HVAC #Semiconductors #WaterTreatment #PrecedenceResearch

🚀 mRNA Synthesis Raw Materials Market: Powering the Next Wave of Biotech Innovation The global mRNA synthesis raw materials market is on a rapid growth trajectory, valued at USD 2.22 billion in 2025 and projected to reach USD 8.37 billion by 2035, growing at a strong 14.21% CAGR. This momentum is driven by expanding mRNA vaccine and therapeutic pipelines, rising biotech investments, and breakthroughs in scalable manufacturing. 🔬 Key Market Highlights • North America led with 41% market share in 2025, while Asia Pacific is the fastest-growing region • Nucleotides dominated by type (40%), with capping agents gaining traction • GMP-grade raw materials held a commanding 58% share, reflecting strict regulatory needs • mRNA vaccines accounted for 46% of applications, while therapeutics show the fastest future growth • Biopharma & biotech companies led end-user demand (47%), with CDMOs rapidly scaling 🤖 AI Is Transforming mRNA Production Artificial intelligence is reshaping the value chain, optimizing nucleotide usage, improving sequence design, forecasting reagent demand, and enabling real-time quality control. From predictive analytics to digital twins, AI is accelerating yield, reducing costs, and strengthening GMP compliance. 💡 What’s Driving the Market Forward? • Rising use of mRNA in oncology, rare diseases, and personalized medicine • Government funding for pandemic preparedness & R&D • Advances in lipid nanoparticles (LNPs) and delivery systems • Growing demand for modified nucleotides to enhance stability and reduce immunogenicity 📈 With innovation accelerating across enzymes, nucleotides, capping reagents, and AI-driven manufacturing, the mRNA ecosystem is moving beyond vaccines toward a new era of scalable, personalized therapeutics. 👉 Explore the full market outlook, competitive landscape, and segment insights: https://lnkd.in/dYtGYDeF You can place an order or ask any questions. Please feel free to contact us at [email protected] |+1 804 441 9344 #MRNA #Biotechnology #LifeSciences #PharmaInnovation #AIinBiotech #Vaccines #Therapeutics #MarketInsights #HealthcareTrends

🚨 Healthcare Policy & Innovation Update | Novartis–US Government Agreement 🚨 Novartis has announced a landmark agreement with the U.S. government aimed at lowering drug prices in the United States while reinforcing long-term investment in innovation, manufacturing, and R&D, a move that could reshape pricing dynamics across the global pharmaceutical landscape. 🔍 Key Highlights of the Agreement As part of this voluntary commitment, Novartis will: ✅ Launch future medicines at comparable prices across high-income countries ✅ Build direct-to-patient access platforms for key therapies Mayzent® (siponimod), Rydapt® (midostaurin), and Tabrecta® (capmatinib) accessible through TrumpRx ✅ Apply to participate in the GENEROUS Model, aimed at improving access within the U.S. Medicaid program ✅ Support initiatives addressing the global imbalance in pharmaceutical innovation investment 🗣️ “This agreement continues our long-term partnership with the U.S. government to advance the development and manufacturing of breakthrough treatments,” said Vas Narasimhan, CEO of Novartis, reinforcing the company’s commitment to patient access and sustainable innovation. 🏗️ Massive U.S. Investment Momentum Earlier this year, Novartis pledged $23 billion over five years to expand its U.S. R&D and manufacturing footprint. Progress so far includes: • A $1.1B biomedical research hub in San Diego, CA • A new flagship manufacturing hub in North Carolina (Raleigh/Durham), enabling end-to-end production across technology platforms • A new radioligand therapy (RLT) manufacturing facility in Carlsbad, CA • Planned RLT manufacturing expansions in Florida and Texas 📌 In recognition of this significant investment, Novartis is expected to receive three years of tariff relief. 💡 Why this matters: This agreement highlights a growing shift toward value-based drug pricing, direct patient access models, and localized manufacturing, setting a precedent for future collaborations between governments and global pharma leaders. 🔎 Want deeper insights into Novartis, U.S. healthcare policy shifts, and emerging pharmaceutical innovations? 👉 Visit Precedence Research and purchase our in-depth market analysis to stay ahead of the curve. https://lnkd.in/eBsVSEsV #HealthcareNews #PharmaInnovation #DrugPricing #Novartis #USHealthcare #PharmaceuticalIndustry #PrecedenceResearch

🚀 Toshiba Expands Zener Diode Portfolio to Strengthen Power Line Protection Toshiba Electronics Europe GmbH has announced the launch of 15 new Zener diodes under its CMZBxxA series, further enhancing protection solutions for power lines in semiconductor devices and electronic equipment. These new devices are designed to safeguard against switching surges and long-duration overvoltage pulses, making them ideal for both consumer and industrial applications. 🔧 What’s New & Improved? The CMZBxxA series features an advanced planar structure, introduced as the successor to the mesa-structured CMZBxx series (now reaching end of life). This innovation delivers: • Lower reverse current and higher reliability, thanks to oxide-film-protected PN junctions • Tighter Zener voltage tolerance, improved from ±10% to ±5% (typ.) • Significantly reduced reverse current (IR) from 10μA to 0.5μA, supporting lower power consumption and simpler circuit design ⚡ Built for Real-World Power Line Challenges Unlike conventional ESD protection diodes, the new Zener diodes are engineered to handle long pulse-width switching surges (up to milliseconds) and overvoltage pulses close to DC common challenges in power supply lines. 📐 Easy Upgrade, No Redesign The CMZBxxA devices retain the same M-FLAT package (2.4mm × 4.7mm × 0.98mm) as their predecessors, enabling seamless upgrades without any PCB layout changes. 🔋 Broad Voltage Coverage The 15-product lineup supports Zener voltages from 12V to 51V (typ.), covering a wide range of commonly used voltage requirements and helping improve overall equipment reliability. 📊 At Precedence Research, we track and analyze the latest innovations shaping the semiconductor and electronics industry. 👉 Visit our website to purchase in-depth market analysis and competitive insights on leading companies and breakthrough technologies like Toshiba’s latest Zener diode advancements. https://lnkd.in/dKZ7W8pw #Semiconductors #PowerElectronics #ZenerDiodes #Toshiba #ElectronicsInnovation #SurgeProtection #IndustrialElectronics #PrecedenceResearch

🚀 AI in Medical Imaging: Powering the Next Era of Precision Diagnostics The global AI in medical imaging market size is evaluated at USD 2.57 trillion in 2026 and predicted USD 22.97 trillion by 2035, expanding at a CAGR of 27.57% from 2026 to 2035. The AI in medical imaging market is undergoing exponential growth reshaping how diseases are detected, diagnosed, and managed worldwide. This rapid expansion underscores AI’s transition from an assistive tool to a core clinical infrastructure in modern healthcare. 🌍 Regional Insights 🔹North America leads with 45% market share (2025), driven by strong R&D ecosystems, FDA approvals, and early adoption across hospitals. 🔹Asia-Pacific is the fastest-growing region (CAGR ~30.8%), powered by government-backed AI strategies, rising healthcare demand, and digital health investments in India, China, and Australia. 🔹India is emerging as a high-impact market through initiatives like Ayushman Bharat Digital Mission, with startups such as Qure.ai and Niramai advancing AI-driven diagnostics. 🔹Europe continues steady growth, led by Germany and the UK, where AI is being embedded into public health systems like the NHS. 🔹South America & MEA are gaining momentum, with Brazil and South Africa leveraging AI to address radiologist shortages and expand diagnostic access. 🧠 Technology & Clinical Highlights 🔹Deep Learning (48% share) dominates, with CNNs driving image recognition and segmentation. 🔹Explainable AI (XAI) is the fastest-growing segment, addressing trust, transparency, and regulatory needs. 🔹CT imaging (37% share) leads today, while MRI is set to grow at ~30% CAGR. 🔹Lung & Pulmonary imaging (22%) remains the largest clinical area, while oncology is the fastest growing. 🔹Edge & embedded AI is accelerating real-time diagnostics especially in emergency and remote care settings. 🏥 End-User & Product Trends 🔹Hospitals lead adoption (65%), supported by high imaging volumes and advanced infrastructure. 🔹Diagnostic imaging centers are scaling fastest, using AI to improve turnaround times and efficiency. 🔹Software solutions (77% share) dominate due to scalability and workflow integration, while AI-enabled hardware is rising rapidly. 🏢 Key Companies Shaping the Market Industry leaders accelerating innovation include: GE HealthCare, Philips, NVIDIA, IBM, Microsoft, Enlitic, Ada Health, and others. Recent milestones - such as NHS UK deploying AI-powered 3D heart imaging, Australia integrating Annalise.ai, and multi-center AI deployments in India demonstrate real-world impact at scale. 📥 Get the full report covering market size, CAGR, segment insights & competitive landscape: https://lnkd.in/dRTfzhKG You can place an order or ask any questions. Please feel free to contact us at [email protected] |+1 804 441 9344 #AIinHealthcare #MedicalImaging #HealthTech #Radiology #DigitalHealth #AIInnovation #FutureOfHealthcare #MedTech #PrecisionMedicine

🚀Global Electrophysiology Ablation Market Surges Ahead with 11.8% CAGR Through 2035 According to the latest analysis by Precedence Research, the global electrophysiology ablation market is entering a transformative growth phase, projected to expand from USD 7.17 billion in 2025 to USD 21.86 billion by 2035, registering a robust CAGR of 11.8%. 📈 What’s fueling this momentum? ✔ Rising prevalence of cardiac arrhythmias, especially atrial fibrillation ✔ Rapid shift toward minimally invasive, catheter-based procedures ✔ Integration of AI-enabled 3D mapping, navigation, and predictive analytics ✔ Breakthrough innovations such as pulsed field ablation (PFA), enhancing safety and efficiency 🩺 Key Market Insights: • North America led with ~41% market share in 2025 • Asia Pacific is expected to be the fastest-growing region through 2035 • Radiofrequency ablation remains the dominant technology • Pulsed field ablation (PFA) is gaining rapid clinical adoption • Atrial fibrillation accounted for 56% of total demand • Hospitals & cardiac centers captured over 63% share 🤖 AI is redefining electrophysiology care by enabling precision ablation, reducing recurrence rates, and supporting personalized post-procedure management, accelerating adoption across advanced cardiac centers worldwide. 🔍 Explore full market size, CAGR, segmentation, regional insights, and competitive landscape: 👉 https://lnkd.in/db4w2g_F You can place an order or ask any questions. Please feel free to contact us at [email protected] |+1 804 441 9344 #Electrophysiology #CardiacAblation #MedicalDevices #AIinHealthcare #MinimallyInvasiveSurgery #DigitalHealth #HealthcareInnovation #MarketResearch #PrecedenceResearch

🚀 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐑𝐞𝐝𝐞𝐟𝐢𝐧𝐢𝐧𝐠 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐆𝐥𝐨𝐛𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 The global digital health market is entering a transformative growth phase. Valued at USD 420.08 billion in 2025, the market is projected to reach USD 1,171.24 billion by 2035, growing at a CAGR of 10.8%. This momentum reflects a fundamental shift in how healthcare is delivered, accessed, and experienced worldwide. 🌍 𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 🔹Europe leads the market with ~34.7% share in 2025, driven by strong digital infrastructure, interoperable EHR frameworks (with countries like Belgium achieving near-universal EHR access), aging demographics, and supportive government policies. 🔹Asia-Pacific is the fastest-growing region (CAGR ~14.4%), fueled by rapid smartphone adoption, AI-driven health analytics, and strong public-sector initiatives. 🔹India stands out with initiatives like Digital India and DISHA, accelerating secure #digitalhealthrecords and nationwide adoption. 🔹North America continues to scale through #telehealth reimbursement reforms, chronic disease management demand, and record venture funding (USD 10.1B across 497 deals in 2024). 🧠 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 & 𝐂𝐨𝐦𝐩𝐨𝐧𝐞𝐧𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 🔹Telehealthcare dominates with ~41% market share, becoming a cornerstone for remote care, chronic disease management, and virtual consultations. 🔹Services account for ~65.7% of total market share, emphasizing the importance of implementation, training, integration, and optimization. 🔹Rapid adoption of #AI, #IoT, #cloudcomputing, big data, wearables, #mHealthapps, and connected health platforms continues to reshape care delivery from reactive to predictive & preventive models. 🏢 𝐊𝐞𝐲 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 Leading organizations shaping the digital health ecosystem include: Philips | athenahealth | Cisco | McKesson | Allscripts | eClinicalWorks | BioTelemetry, Inc. | AdvancedMD. Recent moves such as 98 point 6 acquiring Bright.md and JD Healthcare expanding elderly care platforms in China highlight the sector’s focus on scalability and inclusive care. 📥 Get the full report covering market size, CAGR, segment insights & competitive landscape: https://lnkd.in/dg36-sF5 You can place an order or ask any questions. Please feel free to contact us at [email protected] |+1 804 441 9344 #DigitalHealth #HealthTech #Telehealth #mHealth #AIinHealthcare #HealthcareInnovation #GlobalHealth #EHR #FutureOfHealthcare